Methylenetetrahydrofolate reductase in Parkinson's disease [3]

Annals of Neurology

Volumn 58, Issue 6, 2005, Pages 972-973

  Wüllner, Ullrich ^a   Kölsch, Heike ^a   Linnebank, Michael ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2);

ADULT; AGED; CASE CONTROL STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RISK ASSESSMENT;

HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PARKINSON DISEASE; RISK FACTORS;

EID: 28544445973     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20696     Document Type: Letter

References (5)

1. de Lau LML, Koudstaal PJ, van Meurs JBJ, et al. Methylenetetrahydrofolate reductase C677T genotype and PD. Ann Neurol 2005;57:927-930.
2. Linnebank M, Linnebank A, Jeub M, et al. Lack of genetic dispositions to hyperhomocysteinemia in Alzheimer's disease. Am J Med Genet 2004;131A:101-102.
3. Mudd SH, Levy HL, Kraus JP. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, eds. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 2001;2007-2056.
4. Duan W, Ladenheim B, Cutler RG, et al. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 2002;80:101-110.
5. Sian J, Dexter DT, Lees AJ, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994;36:348-355.